Back to search
Lymphoma, Non-Hodgkin's
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Lymphoma, Non-Hodgkin's trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Lymphoma, Non-Hodgkin's trials you may qualify forFollicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable wit…
The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with…
Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cur…
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Gl…
This will be a phase 1, open-label, dose-escalation and expansion, FIH trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of JBZ-001,…
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whe…
The main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalation), to fur…
This phase I trial studies the side effects and best dose of lenalidomide and ibrutinib in treating patients with B-cell non-Hodgkin lymphoma that has returned…